# Chipscreen Biosciences, Ltd. clinical trials: 42 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with Chipscreen Biosciences, Ltd. as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Chipscreen Biosciences, Ltd.: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/chipscreen-biosciences-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 13, 2026 | NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | Chipscreen Biosciences, Ltd. | Phase 1 | Not yet recruiting | Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma, Diffuse Large B-Cell Lymphoma... | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583771) |
| May 12, 2026 | NCT07580638 | Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes | Chipscreen Biosciences, Ltd. | Observational | Recruiting | T2DM (Type 2 Diabetes Mellitus) | 3,550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07580638) |
| April 9, 2026 | NCT07519265 | Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets | Chipscreen Biosciences, Ltd. | Not applicable | Completed | T2DM (Type 2 Diabetes Mellitus) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519265) |
| April 6, 2026 | NCT07511010 | Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets | Chipscreen Biosciences, Ltd. | Phase 1 | Completed | T2DM (Type 2 Diabetes Mellitus) | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511010) |
| March 3, 2026 | NCT07445295 | Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Chipscreen Biosciences, Ltd. | Phase 3 | Not yet recruiting | Metastatic Pancreatic Ductal Adenocarcinoma | 558 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07445295) |
| February 17, 2026 | NCT07412015 | Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets | Chipscreen Biosciences, Ltd. | Not applicable | Completed | T2DM (Type 2 Diabetes Mellitus) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412015) |
| August 19, 2025 | NCT07129382 | A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis | Chipscreen Biosciences, Ltd. | Phase 1/2 | Recruiting | Plaque Psoriasis | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07129382) |
| April 27, 2025 | NCT06947967 | Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | Chipscreen Biosciences, Ltd. | Phase 3 | Recruiting | Lymphoma, T-Cell, Peripheral | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947967) |
| March 30, 2025 | NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | Chipscreen Biosciences, Ltd. | Phase 1 | Recruiting | Neoplasms, Glioblastoma, Adult, Small Cell Lung Carcinoma (SCLC) | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06902350) |
| July 12, 2024 | NCT06497985 | A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients | Chipscreen Biosciences, Ltd. | Phase 3 | Recruiting | Colorectal Cancer | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06497985) |
| July 9, 2024 | NCT06492915 | Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | Chipscreen Biosciences, Ltd. | Phase 2 | Active not recruiting | Pancreatic Ductal Adenocarcinoma | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492915) |
| February 7, 2024 | NCT06245122 | A Study of CS23546 in Subjects With Advanced Tumors | Chipscreen Biosciences, Ltd. | Phase 1 | Recruiting | Advanced Tumors | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06245122) |
| January 25, 2024 | NCT06224595 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules | Chipscreen Biosciences, Ltd. | Phase 1 | Completed | Healthy | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06224595) |
| August 7, 2023 | NCT05979155 | A Study of NWY001 in Subjects With Advanced Solid Tumors | Chipscreen Biosciences, Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05979155) |
| June 28, 2023 | NCT05922709 | A Clinical Trial of CS12192 in Healthy Subjects | Chipscreen Biosciences, Ltd. | Phase 1 | Completed | Healthy | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05922709) |
| January 12, 2023 | NCT05681273 | Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. | Chipscreen Biosciences, Ltd. | Phase 1 | Completed | T2DM | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05681273) |
| August 29, 2022 | NCT05519865 | A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC | Chipscreen Biosciences, Ltd. | Phase 2 | Completed | Non Small Cell Lung Cancer | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05519865) |
| August 25, 2022 | NCT05515458 | Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function | Chipscreen Biosciences, Ltd. | Phase 1 | Completed | Renal Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05515458) |
| August 25, 2022 | NCT05515445 | Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function | Chipscreen Biosciences, Ltd. | Phase 1 | Completed | Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05515445) |
| August 11, 2022 | NCT05497843 | Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) | Chipscreen Biosciences, Ltd. | Phase 2 | Completed | Soft Tissue Sarcoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05497843) |
| May 12, 2022 | NCT05371899 | Mass Balance Study of \[14C\]Chiauranib | Chipscreen Biosciences, Ltd. | Not applicable | Completed | Small Cell Lung Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05371899) |
| April 26, 2022 | NCT05346601 | Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers | Chipscreen Biosciences, Ltd. | Phase 1 | Completed | Healthy Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05346601) |
| April 20, 2022 | NCT05336721 | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | Chipscreen Biosciences, Ltd. | Phase 2 | Terminated | Triple-negative Breast Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05336721) |
| March 9, 2022 | NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. | Chipscreen Biosciences, Ltd. | Phase 1/2 | Unknown | Small Cell Lung Cancer, Advanced Solid Malignant Tumor | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05271292) |
| January 18, 2022 | NCT05193916 | A Phase II Clinical Trial of Chiglitazar for NASH | Chipscreen Biosciences, Ltd. | Phase 2 | Completed | NASH | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05193916) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 5 |
| Phase 2 | 8 |
| Phase 3 | 10 |
| Not applicable | 3 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Recruiting | 7 |
| Terminated | 2 |
| Not yet recruiting | 2 |
| Unknown | 2 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 7 |
| Small Cell Lung Carcinoma | 5 |
| Recurrence | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Ovarian Neoplasms | 3 |
| Lymphoma, Non-Hodgkin | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lymphoma, T-Cell, Peripheral | 2 |
| Hereditary Sensory and Autonomic Neuropathies | 1 |
| Lymphoma | 1 |
| Diabetes Mellitus | 1 |
| Sarcoma | 1 |
| Carcinoma, Hepatocellular | 1 |
| Renal Insufficiency | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Neoplasms | 1 |
| Glioblastoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Haitian restaurants in the United States](https://specstream.ai/data/businesses/haitian-restaurants/united-states)
- [Bearing suppliers in the United States](https://specstream.ai/data/businesses/bearing-suppliers/united-states)
- [Scale suppliers in the United States](https://specstream.ai/data/businesses/scale-suppliers/united-states)
- [Indo Chinese restaurants in the United States](https://specstream.ai/data/businesses/indo-chinese-restaurants/united-states)
- [Cardiothoracic surgery practices in the United States](https://specstream.ai/data/businesses/cardiothoracic-surgery-practices/united-states)
- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
